20 August 2021 (Friday) - Myeloma

The American Society of Hematology sent a little update on Myeloma today. Some of it went over my head… Knowing that something has gone over my head shows me where I need to be focussing my CPD, doesn’t it…

Here are the highlights in multiple myeloma:
Analyzing Survival Outcomes With Ixazomib-Rd in Relapsed/Refractory Multiple Myeloma
While treatment with ixazomib, lenalidomide, and dexamethasone was shown to improve progression-free survival, recent findings show the triple combination therapy may not prolong overall survival.
FDA Warns of Increased Death Risk for Patients with MM Receiving Melphalan Flufenamide
The FDA requires that Oncopeptides AB suspend enrollment in the OCEAN trial and other ongoing clinical trials involving melphalan flufenamide because of an increased risk of death among patients with multiple myeloma receiving the treatment.
Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Relapsed/Refractory MM
Recent results suggest that combination therapy consisting of carfilzomib and dexamethasone plus isatuximab is associated with improvements in progression-free survival and depth of response.

The August issue explores hematologic conditions in athletes, a blue top tube shortage, and more.

No comments:

Post a Comment